CL
Christopher P Leamon
Vice President of Research

Christopher P Leamon insider trades: Endocyte (ECYT) stock buys and sales

Vice President of Research, Endocyte Last trade Oct 5, 2018 30 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2011
2
Companies
last trade 2018

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Christopher reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 5, 2018ECYT↓ Sell10b5-1$140K
Aug 29, 2018ECYT↓ Sell10b5-1$347K
Jun 12, 2018ECYT↓ Sell10b5-1$197K
Mar 9, 2018ECYT↓ Sell10b5-1$46K
Dec 1, 2017ECYT↓ Sell$117K
Dec 30, 2016ECYT↓ Sell$59K
May 14, 2013ECYT↓ Sell$74K
Aug 16, 2012ECYT↓ Sell$97K
Dec 21, 2011ECYT↑ Buy$16K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Christopher P Leamon's insider trades

Christopher P Leamon is Vice President of Research at Endocyte (ECYT). Since Dec 21, 2011, Christopher has reported 1 open-market purchase worth $16K and 8 sales worth $1.1M on SEC Form 4. There have been no open-market trades in the last 12 months.

4 sales (68% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (13 filings), option exercises (7 filings), shares withheld for taxes (5 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ECYT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.